Fabry's Disease: A Case series report of a Libyan family
DOI:
https://doi.org/10.54361/ljmr.16211Keywords:
Fabry's Disease, a-galactosidase, chronic kidney disease, Enzyme Replacement TherapyAbstract
Introduction Fabry's disease (FD) is a rare disorder due to the very low residual function of alpha galactosidase enzyme causing chronic kidney disease (CKD), with the incidence of 1/40,000 males. Heterozygous females may be asymptomatic. We hereby report a patient having CKD and other clinical findings like, dermatological, neurological and cardiological manifestations and pedigree analysis were strongly suggest the diagnosis of Fabry Disease. Case Presentation: A 40-year-old man with high renal profile the patient is normotensive, non-diabetic, in 2013 had history of left ophthalmoplegia which resulted from acute ischemia in midbrain, in 2014 had bilateral sensory neural hearing loss. In 2019 was noticed that he had a skin rash in a “bathing-trunk” distribution, they are small angiomas, by physical examination patient looks pale, he has mild pedal edema, CNS examination showed 7th, 8th and 9th cranial nerve palsy, his investigations showed raised s. creatinine 3.2 mg/dl, Urine protein++, eGFR 22.4/min/1.73m2. Ultrasound abdomen showed small kidneys and echocardiography showed LVH. A pedigree analysis showed recipient was third in birth order and has two brothers a known case of CKD on regular hemodialysis, The CKD of the brothers was a result of Fabry Disease, was evaluated for a-galactosidase activity which was found markedly decreased (12.10; normal enzyme activity level >60). According to clinical manifestations and strong family history of FD, Conclusion & Recommendations: This case report highlights the importance of careful evaluation of cases of CKD due to unusual causes, particularly when there's positive family history, in order to avoid misdiagnosis and also for early and proper therapy.
Downloads
References
McGovern MM, Desnick RJ. Lysosomal storage diseases. Cecil Textbook of Medicine. In: Goldman L, editor. 21st ed. St. Louis: W.B. Saunders Company; 2000. pp. 1104–7.
Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, etal. Patients with Fabrydisease on dialysis in the United States. Kidney Int. 2002; 61:249–55.
Brady RO, Grabowski GA, Thadhani R. United states: Gardiner-Caldwell Syner Med; 2001. Fabry Disease: Review and New Perspectives; pp. 1– 8.
Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. eISSN:2413-6096 http://www.ljmr.com.ly/Transplantation.2000;69:2337– 9.
Obrador GT, Ojo A, Thadhani R. End-stage renal disease in patients with Fabry disease. J AmSocNephrol.2002;13(Suppl1): S144–6.
Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant. 1996;11(Suppl 1):4– 20.
Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. JAm SocNephrol.2007;18:2609–17.
Alroy J, Sabnis S, Kopp JB. Nanopathology yin Fabry disease. Jam Soc Nephr ol.
2002;13(Suppl1): S134–8.
Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122–38
Batista EC, Carvalho LR, Casarini DE, Carmona AK, dos Santos EL, da Silva ED, et al. ACE activity is modulated by the enzyme a-galactosidase A. J Mol Med (Berl) 2011;89:65– 74
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl. 2009;76: S1– 130
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ali A. Alahrash, Roudaba Betro (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
